(HealthDay News) -— Treatment of heavy menstrual bleeding (HMB) is associated with improvements in health-related quality of life (HRQoL), with greater improvements for women with anemia at baseline, according to a study published online June 9 in ACTA Obstetricia et Gynecologica Scandinavica.

Pirkko Peuranpää, MD, from Hyvinkää Hospital in Finland, and colleagues examined the impact of anemia and iron deficiency on HRQoL in a cohort of 236 women treated for HMB. Participants were randomized to treatment with hysterectomy or levonorgestrel-releasing intrauterine system. Women were classified based on pretreatment hemoglobin (<120g/L [anemic] and ≥120g/L [nonanemic]) and serum ferritin concentrations (<15 and ≥15µg/L). At baseline and at 6 and 12 months, HRQoL was compared between the groups.

At baseline, 27% of women were anemic and 60% were severely iron deficient. The researchers found that hemoglobin had increased in both groups 12 months after treatment, but was still significantly lower in initially anemic vs. nonanemic women (128 vs. 136g/L; P<0.001). At 12 months post-treatment, greater increases were seen for anemic versus nonanemic women in three domain scores of the RAND 36-item health survey (energy, P=0.002; physical functioning, P=0.04; and social functioning, P=0.05), and greater decreases were seen in anxiety (P=0.02) and depression scores (P=0.002).

“Improved HRQoL after treatment of HMB is associated with correction of anemia,” the authors write. “Clinicians should actively screen for anemia in women with HMB and emphasize early iron substitution as an integral part of treatment.”

Continue Reading

Several authors disclosed financial ties to the pharmaceutical industry.

Full Text (subscription or payment may be required)